FluoGuide A/S (STO: FLUO)

Market Cap	555.95M
Revenue (ttm)	1.86M
Net Income (ttm)	-55.47M
Shares Out	13.61M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,513
Open	41.00
Previous Close	41.00
Day's Range	39.50 - 41.45
52-Week Range	36.50 - 96.00
Beta	1.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreeme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2023, SKMO's revenue was 271.13 million, a decrease of -0.30% compared to the previous year's 271.96 million. Earnings were 14.79 million, a decrease of -28.81%.

Financial numbers in DKK